Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The FDA recently held up the U.S. approval based on concerns over the monthly injectable regimen’s manufacturing.
Whether given every four or eight weeks, long-acting injections of cabotegravir and rilpivirine suppressed HIV equally well.
Gilead’s HIV capsid inhibitor might need dosing only every six months
For the first time, researchers are assessing a pairing of a long-acting antiretroviral and a long-acting antibody.
Researchers are working on patches containing tiny needles that deliver medications through the skin.
The agency expressed concerns about the monthly injectable regimen’s chemistry and manufacturing controls.
A small study surveyed individuals about their preferences regarding long-acting injectable antiretroviral treatment.
Here are the HIV treatment news stories with the most views this year.
New forms of treatment and PrEP and, hopefully, an at least partially effective vaccine will be key to fighting the epidemic in the 2020s.
Long-acting injectables may be given once every other month, according to new findings.
Studies indicate that there is a very low likelihood that people with HIV have preexisting resistance to the medication.
As long-acting injectables near approval, daily pill versions of the same drugs show long-term benefit.
A major plus of the implant is that it can be easily removed if necessary.
Calling all U.S. cisgender gay and bi men and trans and gender nonconforming people at risk for the virus.
Recently, ViiV Healthcare applied for approval of the first long-acting injectable HIV regimen.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.